The global dysmenorrhea treatment market is anticipated to grow at a considerable CAGR of 8.1% during the forecast period (2022-2028). Dysmenorrhea is a common gynaecological condition that affects women of all ages and races. It is one of the most commonly diagnosed causes of pelvic pain in women. The symptoms associated with dysmenorrhea include gastrointestinal symptoms such as diarrhoea, nausea, bloating, constipation, or both, along with vomiting and indigestion. According to the National Centre for Biotechnology Information the prevalence of dysmenorrhea can vary between 16% and 91% in women of reproductive age, with severe pain observed in 2% to 29%. Dysmenorrhea is associated with significant impairment in quality of life between 16% to 29% of women. Furthermore, 12% of the monthly school and work activities are lost due to absenteeism because of dysmenorrhea.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dysmenorrhea-treatment-market
Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in May 2020, Mochida Pharmaceutical Co., Ltd announced the launch of DINAGEST Tablets 0.5 mg a therapeutic agent for dysmenorrhea. DINAGEST Tablets 1 mg, a therapeutic agent for endometriosis, was licensed from Jenapharm, a subsidiary of Bayer AG, and developed by Mochida. The drug is marketed in Japan since 2008 and an additional indication, reduction of pain caused by adenomyosis.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Treatment Type
o By Type
- Regions Covered
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Dysmenorrhea Treatment Market Report by Segment
By Treatment Type.
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Hormonal Therapy
By Type
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
A full report of Dysmenorrhea Treatment Market is available at: https://www.omrglobal.com/industry-reports/dysmenorrhea-treatment-market
Dysmenorrhea Treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Bayer AG
- Hoffmann-La Roche Ltd
- SANOFI
- Alvogen Iceland
- Pfizer Inc.
- ObsEva
- Nobelpharma Co., Ltd
- Color Seven Co., Ltd.
- Sun Pharmaceutical Industries Limited
- Beurer GmbH
- Abbott Laboratories
- Taj Pharmaceuticals Ltd
- Myovant Sciences GmbH
- AbbVie Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
